GlassScriptPhysician profile
Jareer Farah
NPI 1073784583
$10,642.89
in general payments reported to CMS, 2019-2025
33 companies · $406 in 2025
The $406 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,526 · 2020: $296 · 2021: $2,448 · 2022: $1,210 · 2023: $2,984 · 2024: $773 · 2025: $406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,799 · Travel and Lodging: $1,364.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,799.25 |
| Travel and Lodging | $1,363.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,883.16 | 2019-2025 | Amplatzer Amulet, Amplatzer Talisman |
| Medtronic, INC. | $1,529.61 | 2021-2023 | Corevalve Evolut R |
| Abiomed | $1,131.33 | 2020-2024 | Impella |
| Edwards Lifesciences Corporation | $607.83 | 2019-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Novartis Pharmaceuticals Corporation | $461.00 | 2019-2023 | |
| Pfizer INC. | $442.59 | 2019-2025 | |
| Boston Scientific Corporation | $295.09 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $265.44 | 2022-2025 | Verquvo |
| Amgen INC. | $251.40 | 2019-2025 | Repatha, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $239.27 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $191.47 | 2021-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $158.09 | 2019-2023 | Brilinta |
| Philips North America LLC | $153.87 | 2019-2023 | |
| Penumbra, INC. | $128.61 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $115.39 | 2020-2024 | Lifevest |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $113.56 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $95.31 | 2019-2023 | |
| Medtronic Vascular, INC. | $78.58 | 2019 | |
| Janssen Pharmaceuticals, INC | $68.37 | 2019-2022 | |
| Esperion Therapeutics, INC. | $59.44 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $57.32 | 2022-2025 | Camzyos, Eliquis |
| Kestra Medical Technology Services, INC. | $57.09 | 2022-2023 | Assure Wcd |
| Cvrx, INC. | $46.14 | 2021-2024 | Barostim Neo System |
| Shockwave Medical, INC | $35.63 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Chiesi USA, INC. | $35.32 | 2019-2023 | Kengreal, Cleviprex |
| Biosense Webster, INC. | $24.07 | 2024 | Na |
| Cardiovascular Systems INC. | $23.39 | 2019 | |
| Scpharmaceuticals INC. | $22.49 | 2024 | |
| Kiniksa Pharmaceuticals International, Plc | $18.27 | 2024 | Arcalyst |
| Medicomp INC | $14.40 | 2021 | |
| Daiichi Sankyo INC. | $13.83 | 2021 | |
| Alnylam Pharmaceuticals INC. | $13.41 | 2022 | |
| Amryt Pharma Holdings LTD | $12.12 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jareer Farah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.